Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
The Oncologist|April 4, 2020
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupHumaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaDaniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experienceAly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Targeted Oncology|February 14, 2019
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic MalignanciesMaja J A de Jonge, Neeltje Steeghs, Martijn P Lolkema, et al.
Investigational New Drugs|July 18, 2013
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsIvan Diaz-Padilla, Hal Hirte, Amit M Oza, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2022
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in CanadaBobby Shayegan, Christopher J D Wallis, Robert J Hamilton, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
The Oncologist|April 4, 2020
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupHumaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial CarcinomaDaniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experienceAly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
Targeted Oncology|February 14, 2019
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic MalignanciesMaja J A de Jonge, Neeltje Steeghs, Martijn P Lolkema, et al.
Investigational New Drugs|July 18, 2013
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsIvan Diaz-Padilla, Hal Hirte, Amit M Oza, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2022
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in CanadaBobby Shayegan, Christopher J D Wallis, Robert J Hamilton, et al.
Pageof 9